1Farmer JA, Gotto AM. Choosing the right lipid- regulating a gent: a guide to selection[J]. Drugs, 1996, 52(5) :649-661.
2Isaacsohn JL, Setaro JF, Nicholas C, et al. Effects of lovastatin therapy on plasminigen activator inhibitor- 1 antigen levels [J ]. Am J Cardiol, 1994, 74(7) :735- 737.
3Corti R, Fuster V, Fayad ZA, et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow - up by high resolution noninvasive magnetic resonance imaging [J ]. Circula-tion, 2002, 106(23) : 2884- 2887.
4Bays HE, Stein EA, Shah AK, et al. Effects of simvastatin on C- reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients[.l ]. Am J Cardlol, 2002, 90 (9) : 942- 946.
5Inoue T, Hayashi M, Takayanagi K, et al. Lipid- lowering therapy with fluvastatin inhibits oxidative modification of low density lipoprotein and improves vascular endothelial function in hypercholesterolemic patients [J]. Atherosclerosis, 2002, 160(2) :369-376.
6Ito MK. Niacin-based therapy for dyslipidemia: past evidence and future advances [ J ]. Am J Manag Care, 2002, 8 ( 12 Suppl) : S315- 322.
7Lea AP, McTavish D. Atorvastatin, a review of its pharmacology and therapeutic potential in the management of hyperlipidemias [J]. Drugs, 1997, 53 (5) : 828 - 847.
8Wu CC, Sy R, Tanphaichitr V, et al. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low - density lipoprotein- cholesterol- a multinational, multicenter, double - blind study [J].J Formos Med Assoc, 2002, 101(7):478-487.
9Athyros VG, Papageorgiou AA, Athyrou VV, et al. Atovastatin versus four statin fibrate combination in patients with familial combined hyperlipidaemia [J ]. J Cardiovasc Risk, 2002, 9 ( 1 ) : 33- 39.
10Mercuro G, Zoncu S, Saiu F, et al. Effect of atovastatin on endothelium dependent vasodilation in postmenopausal women with average serum cholesterol levels [J]. Am J Cardiol, 2002, 90(7) :747-750.
